Euroopan unioni - tšekki - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - mnohočetný myelom - antineoplastická činidla - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Euroopan unioni - tšekki - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekurzorová buněčná lymfoblastická leukémie-lymfom - antineoplastická činidla - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Euroopan unioni - tšekki - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hypercholesterolemie - Činidla modifikující lipidy - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 461 levonorgestrel - intrauterinní inzert - 20mcg/24h - nitrodĚloŽnÍ tĚlÍsko s progestinem

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 461 levonorgestrel - intrauterinní inzert - 20mcg/24h - nitrodĚloŽnÍ tĚlÍsko s progestinem

Euroopan unioni - tšekki - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, skvamózní buňka - antineoplastická činidla - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Tšekki - tšekki - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

intervet international, b.v. - kokcidií vakcíny - suspenze pro perorální suspenzi - Živé parazitární vakcín - kur domácí - kuřata

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

egis pharmaceuticals plc, budapešť array - 19633 mikronizovanÝ levonorgestrel - tableta - 0,75mg - levonorgestrel

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 461 levonorgestrel - tableta dispergovatelná v ústech - 1,5mg - levonorgestrel

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 461 levonorgestrel - tableta - 1,5mg - levonorgestrel